India must use the AYUSH opportunity
For Ayurveda and other AYUSH systems to enter the global mainstream credibly, they must submit to rigorous, independent, and transparent scientific evaluation
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The 2026-27 Union Budget and the upcoming India- Free Trade Agreement (FTA) present a significant opportunity to elevate (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy) systems into the global healthcare mainstream. The Budget has doubled the allocation to ₹4,408 crore and announced new , while the FTA aims to facilitate market access and regulatory recognition in Europe. However, achieving global credibility requires transitioning from cultural assertion to rigorous, independent scientific evaluation.
UPSC Perspectives
Governance
The substantial increase in funding for the and the reflects a strategic shift from treating traditional medicine as an 'alternative silo' to integrating it into the mainstream health ecosystem. The establishment of (modeled on ) signifies a push towards standardizing education, clinical practice, and advanced research. For UPSC Mains (GS 2), this highlights the government's approach to healthcare pluralism—leveraging multiple medical systems to improve accessibility and holistic care. However, the article underscores a critical governance challenge: the need for regulatory harmonisation. If AYUSH products are to compete globally, domestic standards for safety, manufacturing quality (like Good Manufacturing Practices or GMP), and clinical efficacy must align with stringent international benchmarks. The current system, where the promoting Ministry also oversees assessment, creates a conflict of interest, necessitating independent, third-party evaluation mechanisms.
Economic
The integration of AYUSH into the India- (FTA) represents a significant economic opportunity, transitioning traditional medicine from local use to international commercialization. The FTA aims to allow Indian practitioners to use domestic qualifications in the EU and establish clinics, providing regulatory certainty and potentially mutual recognition of safety certifications. For UPSC (GS 3), this illustrates how soft power (cultural heritage) can be monetized through trade diplomacy. The expansion of the global market for Traditional, Complementary, and Alternative Medicine (TCAM) offers India a chance to boost exports and create employment. However, economic success hinges on scientific accountability. The article warns that if commercial claims outpace empirical evidence, it could lead to legal disputes and reputational damage. The economic viability of AYUSH exports is therefore directly tied to investment in rigorous, independently funded clinical trials.
Social
The debate around evidence-based evaluation of traditional medicine often touches upon issues of epistemic dominance and the legacy of colonial medicine, which historically marginalized indigenous healing systems. The article argues that demanding scientific scrutiny is not 'cultural betrayal' but a necessary step for global credibility. Systems like Ayurveda operate on different epistemological foundations compared to biomedicine—viewing health as a state of equilibrium and the body as an interdependent ecological system, rather than focusing on anatomical localization. For UPSC (GS 1/GS 2), understanding these differing paradigms is crucial for formulating inclusive public health policies. The goal should be dialogue and coexistence rather than substitution. Integrating TCAM into public health not only respects cultural knowledge but also offers holistic models of care, provided they are supported by empirical evidence and transparent research methodologies.